Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001012975-26-000212·Bolt Biotherapeutics, Inc.
Schedule 13D ownership disclosure
BOLT BIOTHERAPEUTICS INC
Common Stock, $0.00001 par value · CUSIP: 097702203
Event date: 2026-02-24
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Nan Fung Group Holdings LimitedReported CIK 0001782539
Shares: 87,486 · Class: 4.6%
- NF Investment Holdings Limited
Shares: 87,486 · Class: 4.6%
- Pivotal bioVenture Partners Fund I, L.P.Reported CIK 0001695076
Shares: 52,556 · Class: 2.7%
- Pivotal bioVenture Partners Fund I G.P., L.P.Reported CIK 0001752862
Shares: 52,556 · Class: 2.7%
- Pivotal bioVenture Partners Fund I U.G.P. Ltd.
Shares: 52,556 · Class: 2.7%
- Pivotal Partners Ltd
Shares: 52,556 · Class: 2.7%
- Pivotal Life Sciences Holdings Limited
Shares: 52,556 · Class: 2.7%
- Nan Fung Life Sciences Holdings Limited
Shares: 82,486 · Class: 4.3%
- Permwell Management Limited
Shares: 5,000 · Class: 0.3%
- NFLS Beta Limited
Shares: 29,930 · Class: 1.6%
- NFLS Platform Holdings Limited
Shares: 29,930 · Class: 1.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001012975-26-000212
- Form type
- SCHEDULE 13D/A
- Filer
- Bolt Biotherapeutics, Inc.
- CIK
- CIK 1641281
- Filed
- Feb 26, 2026
- Reporting period
- Feb 24, 2026
- Description
- Schedule 13D beneficial ownership